Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | PRIME H&N: neoadjuvant dostarlimab and niraparib in HPV- HSNCC

Luigi Lorini • 16 Sep 2024
ESMO 2024
Head and Neck Cancer Antibodies Checkpoint Inhibitors Dostarlimab Niraparib
PRIME H&N

Luigi Lorini, MD, Humanitas Research Hospital, Rozzano, Italy, discusses the Phase II PRIME H&N trial of neoadjuvant dostarlimab and niraparib in patients with locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). 39 patients were enrolled, and a majority of treatment-related adverse events, which were mostly grade 1-2, were manageable. Further analyses for efficacy and primary endpoints are ongoing. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Luigi Lorini

Advances in immunotherapy for head and neck squamous cell carcinoma
2:58
Advances in immunotherapy for head and neck squamous cell carcinoma
Luigi Lorini • 16 Sep 2024
PD-L1 expression concordance between primary and recurrent head and neck cancer
1:58
PD-L1 expression concordance between primary and recurrent head and neck cancer
Luigi Lorini • 16 Sep 2024

Related Videos

IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
0:34
IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
Satoaki Nakamura • 16 May 2026
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
0:41
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
Satoaki Nakamura • 16 May 2026
Can IMRT alone be used for higher-risk oropharyngeal cancer?
0:42
Can IMRT alone be used for higher-risk oropharyngeal cancer?
Satoaki Nakamura • 16 May 2026
Could cemiplimab replace HHI therapy in BCCHN?
0:36
Could cemiplimab replace HHI therapy in BCCHN?
Hannah Kenny • 30 May 2026
The content of VJOncology is intended for healthcare professionals